| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
From the Department of Rheumatology,* Experimental Rheumatology and Advanced Therapeutics, Radboud University Nijmegen Medical Center, Nijmegen, The Netherlands; the Department of Pharmacology, Section AutoImmunity, Organon NV, Oss, The Netherlands; and the Novartis Institutes for Biomedical Research, Basel, Switzerland
Rheumatoid arthritis is characterized by an intermittent course of disease with alternate periods of remission and relapse. T cells, and in particular the T-cell cytokine interleukin-17 (IL-17), are expected to be involved in arthritic flares. Here, we report that neutralizing endogenous IL-17 during reactivation of antigen-induced arthritis prevents joint inflammation and bone erosion. Synovial IL-17 mRNA expression was clearly up-regulated during primary arthritis and was further enhanced after antigen rechallenge. Neutralization of IL-17 significantly prevented joint swelling at day 1 of flare and significantly suppressed joint inflammation and cartilage proteoglycan depletion at day 4, as assessed by histology. Blocking IL-17 also clearly reduced bone erosions. Cathepsin K, a marker of osteoclast-like activity, and synovial RANKL mRNA expression were both suppressed. The degree of bone erosions strongly correlated with the severity of joint inflammation, suggesting that anti-IL-17 treatment reduced bone erosion by suppressing joint inflammation. Interestingly, blocking IL-17 suppressed synovial expression of both IL-1ß and tumor necrosis factor-
, whereas blocking IL-1 did not affect tumor necrosis factor- levels. These data indicate that IL-17 is an important upstream mediator in joint pathology during flare-up of experimental arthritis.
This article has been cited by other articles:
 |
|
 |
|
  P. D. Doodes, Y. Cao, K. M. Hamel, Y. Wang, B. Farkas, Y. Iwakura, and A. Finnegan Development of Proteoglycan-Induced Arthritis Is Independent of IL-17 J. Immunol., July 1, 2008; 181(1): 329 - 337. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Lorenzo, M. Horowitz, and Y. Choi Osteoimmunology: Interactions of the Bone and Immune System Endocr. Rev., June 1, 2008; 29(4): 403 - 440. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. M. Elias, A. Laurence, T. S. Davidson, G. Stephens, Y. Kanno, E. M. Shevach, and J. J. O'Shea Retinoic acid inhibits Th17 polarization and enhances FoxP3 expression through a Stat-3/Stat-5 independent signaling pathway Blood, February 1, 2008; 111(3): 1013 - 1020. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. M. Irmler, M. Gajda, and R. Brauer Exacerbation of Antigen-Induced Arthritis in IFN-{gamma}-Deficient Mice As a Result of Unrestricted IL-17 Response J. Immunol., November 1, 2007; 179(9): 6228 - 6236. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. B van den Berg, P. L van Lent, L. A B Joosten, S. Abdollahi-Roodsaz, and M. I Koenders Amplifying elements of arthritis and joint destruction Ann Rheum Dis, November 1, 2007; 66(suppl_3): iii45 - iii48. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Coppieters, P. Dewint, K. Van Beneden, P. Jacques, S. Seeuws, G. Verbruggen, D. Deforce, and D. Elewaut NKT cells: manipulable managers of joint inflammation Rheumatology, April 1, 2007; 46(4): 565 - 571. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. H. Hofstetter, K. V. Toyka, M. Tary-Lehmann, and P. V. Lehmann Kinetics and Organ Distribution of IL-17-Producing CD4 Cells in Proteolipid Protein 139-151 Peptide-Induced Experimental Autoimmune Encephalomyelitis of SJL Mice J. Immunol., February 1, 2007; 178(3): 1372 - 1378. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Schnyder-Candrian, D. Togbe, I. Couillin, I. Mercier, F. Brombacher, V. Quesniaux, F. Fossiez, B. Ryffel, and B. Schnyder Interleukin-17 is a negative regulator of established allergic asthma J. Exp. Med., November 27, 2006; 203(12): 2715 - 2725. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M I Koenders, L A B Joosten, and W B van den Berg Potential new targets in arthritis therapy: interleukin (IL)-17 and its relation to tumour necrosis factor and IL-1 in experimental arthritis Ann Rheum Dis, November 1, 2006; 65(suppl_3): iii29 - iii33. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Sutton, C. Brereton, B. Keogh, K. H.G. Mills, and E. C. Lavelle A crucial role for interleukin (IL)-1 in the induction of IL-17-producing T cells that mediate autoimmune encephalomyelitis J. Exp. Med., July 10, 2006; 203(7): 1685 - 1691. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Toy, D. Kugler, M. Wolfson, T. V. Bos, J. Gurgel, J. Derry, J. Tocker, and J. Peschon Cutting Edge: Interleukin 17 Signals through a Heteromeric Receptor Complex J. Immunol., July 1, 2006; 177(1): 36 - 39. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. I. Koenders, E. Lubberts, F. A. J. van de Loo, B. Oppers-Walgreen, L. van den Bersselaar, M. M. Helsen, J. K. Kolls, F. E. Di Padova, L. A. B. Joosten, and W. B. van den Berg Interleukin-17 Acts Independently of TNF-{alpha} under Arthritic Conditions J. Immunol., May 15, 2006; 176(10): 6262 - 6269. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M.-L. Cho, J.-W. Kang, Y.-M. Moon, H.-J. Nam, J.-Y. Jhun, S.-B. Heo, H.-T. Jin, S.-Y. Min, J.-H. Ju, K.-S. Park, et al. STAT3 and NF-{kappa}B Signal Pathway Is Required for IL-23-Mediated IL-17 Production in Spontaneous Arthritis Animal Model IL-1 Receptor Antagonist-Deficient Mice J. Immunol., May 1, 2006; 176(9): 5652 - 5661. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
